<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Androl Urol</journal-id><journal-id journal-id-type="iso-abbrev">Transl Androl Urol</journal-id><journal-id journal-id-type="publisher-id">TAU</journal-id><journal-title-group><journal-title>Translational Andrology and Urology</journal-title></journal-title-group><issn pub-type="epub">2223-4691</issn><publisher><publisher-name>AME Publishing Company</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4842617</article-id><article-id pub-id-type="publisher-id">tau-05-S1-AB004</article-id><article-id pub-id-type="doi">10.21037/tau.2016.s004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Plenary Session</subject></subj-group></article-categories><title-group><article-title>AB004. New technology and therapy for bladder cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Max</given-names></name></contrib><aff id="aff1">Department of Urology, University of California, San Francisco, CA, <country>USA</country></aff></contrib-group><pub-date pub-type="epub-ppub"><month>4</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>4</month><year>2016</year></pub-date><volume>5</volume><issue>Suppl 1</issue><elocation-id>AB004</elocation-id><permissions><copyright-statement>2016 Translational Andrology and Urology. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Translational Andrology and Urology.</copyright-holder></permissions><abstract><p>Urothelial carcinoma of the bladder remains a significant oncologic problem throughout the world and is a source of both morbidity and mortality. Despite advances in the understanding of disease and recent molecular data from The Cancer Genome Atlas, the clinical management of disease has not fundamentally changed over the past decade. In this lecture, we will discuss (I) new technology in the detection and monitoring of non-invasive disease (blue-light and narrow band imaging); (II) the role of lymphadenectomy at the time of cystectomy; (III) a novel risk stratification tool predicting prognosis after cystectomy; and (IV) systemic therapies and clinical trials for advanced and refractory disease.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>New technology</kwd><kwd>therapy</kwd><kwd>bladder cancer</kwd></kwd-group></article-meta></front></article>